title: Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
abstract: OBJECTIVE
  To compare the effects of low-dose transdermal estradiol (E2)/norethisterone acetate (NETA) patches (Estalis 25/125) with low-dose oral E2/NETA (Activelle) on cardiovascular biochemical markers after 12 and 52 weeks of treatment in postmenopausal women with intact uteri.
  
  
  METHODS
  Participants were randomly assigned to receive either transdermal E2/NETA (delivering daily doses of 25 microg E2 and 125 microg NETA, applied every 3-4 d) or oral E2/NETA (1 mg E2 and 0.5 mg NETA, given daily) in this open-label study. The following markers or their stable metabolites in serum or urine were assessed: P-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, matrix metalloproteinase-9, homocysteine, cyclic guanosine monophosphate, serotonin, prostacyclin, thromboxane, and urodilatin.
  
  
  RESULTS
  Significant decreases were found for P-selectin, intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and homocysteine for both hormone therapy (HT) regimens compared with baseline. Matrix metalloproteinase-9 was increased only by oral HT. The urinary concentrations of cyclic guanosine monophosphate, the ratio of prostacyclin to thromboxane metabolite, and the serotonin metabolite were significantly increased for both HT application modes, although the oral treatment showed a significantly greater increase than the transdermal one with respect to baseline. Urodilatin excretion was increased only by the oral regimen.
  
  
  CONCLUSIONS
  Low-dose transdermal and oral HTs using E2 and NETA elicit favorable effects on cardiovascular biochemical markers. For most markers the magnitude of changes found were similar with respect to baseline; however, in some cases oral HT led to a significantly greater change, whereas in other cases the transdermal formulations seemed to provide greater benefits. Whether these differences may be attributed to the different administration routes or to different pharmacokinetic properties remains an open question. Overall low-dose transdermal HT seems to provoke the same benefit on the cardiovascular system as oral HT, as suggested by the results on vascular markers.
authors.affiliation: Department of Endocrinology and Menopause, University Women's Hospital, Tübingen, Germany. endo.meno@med.uni-uebingen.de
authors.forename: Alfred O
authors.initials: AO
authors.lastname: Mueck
authors.forename: Andrea R
authors.initials: AR
authors.lastname: Genazzani
authors.forename: Göran
authors.initials: G
authors.lastname: Samsioe
authors.forename: Ivana
authors.initials: I
authors.lastname: Vukovic-Wysocki
authors.forename: Harald
authors.initials: H
authors.lastname: Seeger
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D004311:Double-Blind Method; D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D004730:Endothelium, Vascular; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate; D017698:Postmenopause; D013557:Switzerland; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004958:Estradiol; D000077563:Norethindrone Acetate; D009640:Norethindrone